Status:
COMPLETED
Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum
Lead Sponsor:
University of Missouri-Columbia
Conditions:
Type 2 Diabetes
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
Our overall goal is to advance our understanding of the contribution of the carotid body chemoreceptors in glucose regulation and the development of type 2 diabetes.
Eligibility Criteria
Inclusion
- healthy,
- type 2 diabetes
- BMI 18-40 kg/m2,
- non-pregnant,
- non-breastfeeding,
- non-nicotine users.
Exclusion
- cardiovascular disease including myocardial infarction, heart failure, coronary artery disease, stroke;
- renal or hepatic diseases;
- active cancer;
- autoimmune diseases;
- immunosuppressant therapy;
- excessive alcohol consumption (\>14 drinks/week);
- current nicotine use;
- foot ulcers;
- diabetic neuropathy;
- medication directly influencing sympathetic nervous system activity
Key Trial Info
Start Date :
September 9 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 10 2023
Estimated Enrollment :
22 Patients enrolled
Trial Details
Trial ID
NCT05219994
Start Date
September 9 2020
End Date
May 10 2023
Last Update
July 27 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Missouri
Columbia, Missouri, United States, 65211